UROGEN PHARMA LTD (URGN) Stock Fundamental Analysis

NASDAQ:URGN • IL0011407140

19.02 USD
-2.68 (-12.35%)
At close: Mar 2, 2026
20.5 USD
+1.48 (+7.78%)
After Hours: 3/2/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to URGN. URGN was compared to 520 industry peers in the Biotechnology industry. Both the profitability and financial health of URGN have multiple concerns. URGN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • URGN had negative earnings in the past year.
  • URGN had a negative operating cash flow in the past year.
  • URGN had negative earnings in each of the past 5 years.
  • URGN had a negative operating cash flow in each of the past 5 years.
URGN Yearly Net Income VS EBIT VS OCF VS FCFURGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • With a Return On Assets value of -88.97%, URGN is not doing good in the industry: 71.73% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -88.97%
ROE N/A
ROIC N/A
ROA(3y)-60.9%
ROA(5y)-76.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
URGN Yearly ROA, ROE, ROICURGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

  • URGN has a Gross Margin of 87.95%. This is amongst the best in the industry. URGN outperforms 89.81% of its industry peers.
  • In the last couple of years the Gross Margin of URGN has declined.
  • The Profit Margin and Operating Margin are not available for URGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.33%
GM growth 5Y-2.05%
URGN Yearly Profit, Operating, Gross MarginsURGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • URGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for URGN has been increased compared to 1 year ago.
  • The number of shares outstanding for URGN has been increased compared to 5 years ago.
  • Compared to 1 year ago, URGN has an improved debt to assets ratio.
URGN Yearly Shares OutstandingURGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
URGN Yearly Total Debt VS Total AssetsURGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • URGN has an Altman-Z score of -6.07. This is a bad value and indicates that URGN is not financially healthy and even has some risk of bankruptcy.
  • URGN has a Altman-Z score of -6.07. This is in the lower half of the industry: URGN underperforms 64.23% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.07
ROIC/WACCN/A
WACC8.07%
URGN Yearly LT Debt VS Equity VS FCFURGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • URGN has a Current Ratio of 3.99. This indicates that URGN is financially healthy and has no problem in meeting its short term obligations.
  • URGN has a Current ratio (3.99) which is comparable to the rest of the industry.
  • A Quick Ratio of 3.79 indicates that URGN has no problem at all paying its short term obligations.
  • The Quick ratio of URGN (3.79) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.99
Quick Ratio 3.79
URGN Yearly Current Assets VS Current LiabilitesURGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • URGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.84%.
  • URGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.00%.
  • The Revenue has been growing by 438.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-9.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.45%
Revenue 1Y (TTM)8%
Revenue growth 3Y23.46%
Revenue growth 5Y438.3%
Sales Q2Q%9.04%

3.2 Future

  • Based on estimates for the next years, URGN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.23% on average per year.
  • The Revenue is expected to grow by 50.72% on average over the next years. This is a very strong growth
EPS Next Y-0.24%
EPS Next 2Y27.66%
EPS Next 3Y30.81%
EPS Next 5Y28.23%
Revenue Next Year22.94%
Revenue Next 2Y61.09%
Revenue Next 3Y62.31%
Revenue Next 5Y50.72%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
URGN Yearly Revenue VS EstimatesURGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
URGN Yearly EPS VS EstimatesURGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for URGN. In the last year negative earnings were reported.
  • Also next year URGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
URGN Price Earnings VS Forward Price EarningsURGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
URGN Per share dataURGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as URGN's earnings are expected to grow with 30.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.66%
EPS Next 3Y30.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • URGN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UROGEN PHARMA LTD

NASDAQ:URGN (3/2/2026, 8:00:02 PM)

After market: 20.5 +1.48 (+7.78%)

19.02

-2.68 (-12.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-02
Inst Owners99.72%
Inst Owner Change-3.02%
Ins Owners2.07%
Ins Owner Change0.36%
Market Cap890.33M
Revenue(TTM)96.52M
Net Income(TTM)-164.64M
Analysts84.29
Price Target35.96 (89.06%)
Short Float %23.24%
Short Ratio13.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.58%
Min EPS beat(2)-23.47%
Max EPS beat(2)2.31%
EPS beat(4)1
Avg EPS beat(4)-10.71%
Min EPS beat(4)-23.47%
Max EPS beat(4)2.31%
EPS beat(8)2
Avg EPS beat(8)-3.71%
EPS beat(12)5
Avg EPS beat(12)-0.39%
EPS beat(16)8
Avg EPS beat(16)0.67%
Revenue beat(2)1
Avg Revenue beat(2)-7.98%
Min Revenue beat(2)-18.58%
Max Revenue beat(2)2.61%
Revenue beat(4)1
Avg Revenue beat(4)-8.74%
Min Revenue beat(4)-18.58%
Max Revenue beat(4)2.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.89%
Revenue beat(12)5
Avg Revenue beat(12)-4.68%
Revenue beat(16)5
Avg Revenue beat(16)-6.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.75%
EPS NQ rev (3m)-4.15%
EPS NY rev (1m)-0.63%
EPS NY rev (3m)0.1%
Revenue NQ rev (1m)-0.53%
Revenue NQ rev (3m)-3.69%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)-6.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.22
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.46
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-2.95
FCFYN/A
OCF(TTM)-2.94
OCFYN/A
SpS2.06
BVpS-2.47
TBVpS-2.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -88.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.95%
FCFM N/A
ROA(3y)-60.9%
ROA(5y)-76.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.33%
GM growth 5Y-2.05%
F-Score2
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -121.32%
Cap/Sales 0.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.99
Quick Ratio 3.79
Altman-Z -6.07
F-Score2
WACC8.07%
ROIC/WACCN/A
Cap/Depr(3y)47.01%
Cap/Depr(5y)104.37%
Cap/Sales(3y)0.32%
Cap/Sales(5y)2.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.45%
EPS Next Y-0.24%
EPS Next 2Y27.66%
EPS Next 3Y30.81%
EPS Next 5Y28.23%
Revenue 1Y (TTM)8%
Revenue growth 3Y23.46%
Revenue growth 5Y438.3%
Sales Q2Q%9.04%
Revenue Next Year22.94%
Revenue Next 2Y61.09%
Revenue Next 3Y62.31%
Revenue Next 5Y50.72%
EBIT growth 1Y-59.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.16%
EBIT Next 3Y33.7%
EBIT Next 5YN/A
FCF growth 1Y-61.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.8%
OCF growth 3YN/A
OCF growth 5YN/A

UROGEN PHARMA LTD / URGN FAQ

What is the fundamental rating for URGN stock?

ChartMill assigns a fundamental rating of 3 / 10 to URGN.


Can you provide the valuation status for UROGEN PHARMA LTD?

ChartMill assigns a valuation rating of 1 / 10 to UROGEN PHARMA LTD (URGN). This can be considered as Overvalued.


Can you provide the profitability details for UROGEN PHARMA LTD?

UROGEN PHARMA LTD (URGN) has a profitability rating of 1 / 10.